A first-of-its-kind artificial intelligence (AI)-based neural network can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue.

The beauty industry has an update, AI and DNA technology are transforming skincare by offering personalised, high-tech ...

"When we announced one million profiles analyzed in 2022, it was a landmark moment in the evolution of data-driven medicine," said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of ...

A first-of-its-kind artificial intelligence (AI)-based neural network can rapidly analyze and interpret millions of cells from a patient sample, predicting molecular changes in the tissue. It can ...

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Artificial Intelligence (AI)-based healthcare solutions company Tempus AI TEM has continued to capture investors’ attention despite reporting weaker-than-expected fourth-quarter 2024 results on Feb.

JAKARTA, INDONESIA / ACCESS Newswire / March 10, 2025 / REGENE Genomics, a pioneer in bioinformatics and genomics-based ...

Myriad Genetics, Inc. has announced a strategic collaboration with PATHOMIQ, Inc., which allows Myriad to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer ...

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against the other AI stocks in ...